Tags

Type your tag names separated by a space and hit enter

Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
Vaccine. 2016 12 07; 34(50):6426-6435.V

Abstract

BACKGROUND

A tetravalent dengue vaccine demonstrated its protective efficacy in two phase III efficacy studies. Results from these studies were used to derive vaccination impact in the five Asian (Indonesia, Malaysia, Philippines, Thailand, Vietnam) and the five Latin American countries (Brazil, Colombia, Honduras, Mexico and Puerto Rico) participating in these trials.

METHODS

Vaccination impact was investigated with an age-structured, host-vector, serotype-specific compartmental model. Parameters related to vaccine efficacy and levels of dengue transmission were estimated using data collected during the phase III efficacy studies. Several vaccination programs, including routine vaccination at different ages with and without large catch-up campaigns, were investigated.

RESULTS

All vaccination programs explored translated into significant reductions in dengue cases at the population level over the first 10years following vaccine introduction and beyond. The most efficient age for vaccination varied according to transmission intensity and 9years was close to the most efficient age across all settings. The combination of routine vaccination and large catch-up campaigns was found to enable a rapid reduction of dengue burden after vaccine introduction.

CONCLUSION

Our analysis suggests that dengue vaccination can significantly reduce the public health impact of dengue in countries where the disease is endemic.

Authors+Show Affiliations

Vaccination Value Modeling, Sanofi Pasteur, Lyon, France. Electronic address: laurent.coudeville@sanofipasteur.com.Vaccination Value Modeling, Sanofi Pasteur, Lyon, France.Global Epidemiology, Sanofi Pasteur, Lyon, France.Research & Development, Sanofi Pasteur, Lyon, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27601343

Citation

Coudeville, Laurent, et al. "Potential Impact of Dengue Vaccination: Insights From Two Large-scale Phase III Trials With a Tetravalent Dengue Vaccine." Vaccine, vol. 34, no. 50, 2016, pp. 6426-6435.
Coudeville L, Baurin N, L'Azou M, et al. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine. 2016;34(50):6426-6435.
Coudeville, L., Baurin, N., L'Azou, M., & Guy, B. (2016). Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine, 34(50), 6426-6435. https://doi.org/10.1016/j.vaccine.2016.08.050
Coudeville L, et al. Potential Impact of Dengue Vaccination: Insights From Two Large-scale Phase III Trials With a Tetravalent Dengue Vaccine. Vaccine. 2016 12 7;34(50):6426-6435. PubMed PMID: 27601343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. AU - Coudeville,Laurent, AU - Baurin,Nicolas, AU - L'Azou,Maïna, AU - Guy,Bruno, Y1 - 2016/09/03/ PY - 2015/08/13/received PY - 2016/08/11/revised PY - 2016/08/16/accepted PY - 2016/11/5/pubmed PY - 2017/12/16/medline PY - 2016/9/8/entrez KW - Dengue KW - Dengue vaccines KW - Epidemiology KW - Prevention & control SP - 6426 EP - 6435 JF - Vaccine JO - Vaccine VL - 34 IS - 50 N2 - BACKGROUND: A tetravalent dengue vaccine demonstrated its protective efficacy in two phase III efficacy studies. Results from these studies were used to derive vaccination impact in the five Asian (Indonesia, Malaysia, Philippines, Thailand, Vietnam) and the five Latin American countries (Brazil, Colombia, Honduras, Mexico and Puerto Rico) participating in these trials. METHODS: Vaccination impact was investigated with an age-structured, host-vector, serotype-specific compartmental model. Parameters related to vaccine efficacy and levels of dengue transmission were estimated using data collected during the phase III efficacy studies. Several vaccination programs, including routine vaccination at different ages with and without large catch-up campaigns, were investigated. RESULTS: All vaccination programs explored translated into significant reductions in dengue cases at the population level over the first 10years following vaccine introduction and beyond. The most efficient age for vaccination varied according to transmission intensity and 9years was close to the most efficient age across all settings. The combination of routine vaccination and large catch-up campaigns was found to enable a rapid reduction of dengue burden after vaccine introduction. CONCLUSION: Our analysis suggests that dengue vaccination can significantly reduce the public health impact of dengue in countries where the disease is endemic. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/27601343/Potential_impact_of_dengue_vaccination:_Insights_from_two_large_scale_phase_III_trials_with_a_tetravalent_dengue_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(16)30735-6 DB - PRIME DP - Unbound Medicine ER -